Emyria Launches Global Platform to Sell Clinical Infrastructure to Drug Sponsors
Emyria launches Empax Global Partnership Program to capture international drug sponsor revenue
Emyria has launched a global services platform that transforms its existing clinical infrastructure into a revenue-generating asset for international drug sponsors. The Empax Global Partnership Program establishes a dual-revenue model combining existing reimbursed patient treatments with new high-margin, sponsor-funded services. The program is already operational with North American sponsor Psyence Group (CSE: PSYG, OTCQB: PSYGF), demonstrating immediate commercial validation as the company supports delivery work for a Phase IIb trial in Adjustment Disorder in patients with advanced cancer. This launch coincides with a US Executive Order aimed at accelerating psychedelic research, creating regulatory tailwinds for demand as more than 50 psychedelic-assisted therapy programs progress through global clinical development.
This strategic shift pivots Emyria from a domestic treatment provider to a global platform play, unlocking a new addressable market of international sponsors requiring clinical delivery infrastructure.
When big ASX news breaks, our subscribers know first
Why clinical delivery infrastructure is the emerging bottleneck
Unlike traditional pharmaceuticals that patients can take at home, psychedelic-assisted therapies demand operational requirements that differentiate them fundamentally from conventional drug development models. These treatments require:
- Intensive psychotherapy integrated throughout the treatment protocol
- Long-duration treatment sessions lasting several hours under direct supervision
- Purpose-built clinical environments designed for safety and therapeutic efficacy
- Highly trained, multidisciplinary teams including specialist psychiatrists and therapists
As a result, clinical delivery capacity—not drug development—is emerging as the primary constraint to global rollout. The recent US Executive Order focused on accelerating research into psychedelic drugs to expedite treatments for serious mental illness signals regulatory momentum that will intensify this bottleneck.
For investors, this creates a critical dynamic: there are more drugs in development than there is infrastructure to deliver them. Companies developing these treatments require partners like Emyria who have already constructed the specialised clinical environments, trained the workforce, and established the governance frameworks necessary for compliant delivery. This structural supply shortage positions Emyria’s existing infrastructure as a scarce asset with pricing power.
Emyria’s clinical network represents years of difficult-to-replicate investment
Emyria’s Empax network has been constructed over multiple years and encompasses components that new entrants cannot quickly replicate. The platform comprises a trained workforce of approximately 100 therapists and specialist psychiatrists, established treatment programmes across PTSD and treatment-resistant depression, and a geographic footprint spanning Perth, Brisbane, and the Mornington Peninsula, with NSW recruitment currently underway.
The company has published 12-month durable remission data in treatment-resistant PTSD, providing clinical credibility that validates its delivery model in complex patient populations. This evidence base, combined with operational infrastructure across multiple sites, establishes Emyria as a trusted clinical delivery partner.
The platform’s five key capabilities demonstrate the depth of investment required:
- Established treatment programmes across PTSD and treatment-resistant depression
- National patient access pathways with strong referral demand
- Trained workforce of ~100 therapists and specialist psychiatrists
- Purpose-built clinical environments including private hospital infrastructure
- Advanced clinical governance including TGA engagement, licensing, ethics approvals, drug logistics and protocol design
The multi-year lead time to construct this infrastructure creates a competitive moat. New entrants face significant barriers: recruiting and training specialist clinicians, securing appropriate clinical facilities, establishing regulatory approvals, and building the operational systems required for compliant delivery at scale. Emyria has already absorbed these costs and overcome these hurdles.
The commercial model—high margin and capital light
The Empax Global Partnership Program commercialises existing infrastructure without requiring significant new capital investment. International drug sponsors engage Emyria to plan and execute clinical delivery, leveraging already-operational infrastructure, clinicians and governance systems.
This model provides sponsors with three key benefits: rapid deployment of complex clinical protocols, reduced execution risk through partnering with an experienced operator, and efficient scaling from clinical trials through to commercial rollout. Sponsor-funded clinical delivery is expected to command premium commercial rates, reflecting the complexity and scarcity of the required expertise and infrastructure.
Emyria reports positive inbound interest from global CROs and drug sponsors, with fees generated on normal commercial terms based on agreed services. Importantly, the capital-light nature of this model means incremental revenue from sponsor services flows through the existing cost base, supporting margin expansion without proportional cost increases.
Psyence Group partnership validates the platform
The current operational engagement with Psyence Group (CSE: PSYG, OTCQB: PSYGF) provides proof of concept for the Empax Global Partnership Program. Emyria is supporting delivery work for Psyence’s Phase IIb trial in Adjustment Disorder in patients with advanced cancer, demonstrating that its platform is already operational, compliant and trusted by international developers.
The Empax Global Partnership Program formalises this offering for the broader sponsor community and is expected to generate additive services revenue without diverting focus from Emyria’s growing patient capacity across existing sites. This demonstrates the platform is not a future ambition but a current revenue opportunity already generating commercial activity.
Greg Hutchinson, Executive Chair
“The experience and infrastructure required to safely deliver these therapies in complex patient populations is scarce and highly valuable. Emyria has spent years building this capability. The Empax Global Partnership Program makes that capability available to international drug sponsors developing the next generation of mental health treatments. We are already delivering for Psyence Group and are seeing positive inbound interest from sponsors and CROs seeking scalable, compliant clinical delivery solutions. Our ambition is to play a leading global role in enabling these therapies to reach patients at scale, while generating high-margin, capital-light revenue for the Company.”
The live commercial engagement validates Emyria’s infrastructure as fit-for-purpose for international sponsors navigating complex regulatory requirements and clinical delivery challenges.
Market context—over 50 programmes in global development
According to Psychedelic Alpha data, more than 50 psychedelic-assisted therapy programmes are currently in global clinical development, targeting large and under-served patient populations across PTSD, treatment-resistant depression and other serious mental health conditions.
The US Executive Order focused on accelerating research into psychedelic drugs to expedite medical treatments for serious mental illness provides regulatory tailwinds that signal accelerated pathways for these programmes. This government and regulatory momentum, particularly in the United States, reinforces the structural demand for clinical delivery infrastructure.
Emyria is well-positioned to capture demand as these programmes progress towards commercialisation. The company’s dual-revenue model positions it to benefit from both the clinical trial phase and post-approval commercial rollout.
| Revenue Stream | Funding Source | Margin Profile | Status |
|---|---|---|---|
| Patient treatment programmes | Healthcare reimbursement | Established | Operational across multiple sites |
| Sponsor-funded services | International drug sponsors/CROs | High margin, capital light | Launched; Psyence Group engaged |
The regulatory and development momentum creates a structural demand tailwind for Emyria’s services over the medium term as programmes advance through clinical development and move towards commercialisation.
The next major ASX story will hit our subscribers first
What comes next for Emyria
The immediate forward focus centres on converting inbound CRO and sponsor interest into contracted engagements. Emyria continues to expand patient treatment capacity across existing and new sites, with NSW recruitment representing the next geographic milestone.
The dual-revenue model provides the strategic foundation for scaling. Reimbursed patient programmes continue to grow whilst sponsor-funded services create a high-margin incremental revenue stream that leverages the same infrastructure. This structure allows Emyria to capture value from both domestic treatment delivery and international sponsor demand without requiring significant additional capital investment.
The launch of the Empax Global Partnership Program marks a strategic inflection point, transitioning Emyria from a domestic clinical provider to a global services platform with multiple revenue streams positioned to benefit from structural growth in psychedelic-assisted therapy development and delivery.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, complete with in-depth analysis. Get ahead on Healthcare and Biotech announcements before the market moves. Click the “Free Alerts” button at StockWire X to start receiving real-time alerts the moment news breaks.